Myra Widjojoatmodjo
Myra Widjojoatmodjo is Director, Janssen Pharmaceutical Companies of Johnson & Johnson, The Netherlands.
JournalEvolution of GMO requirements for innovative investigational medicinal products upon transition to the EU CTR
The EU CTR replaced the EU CTD on 31 January 2022, which impacts investigational medicinal products that fall under genetically modified organisms (GMO-IMPs).